IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Three Optima for ALK Positive Lung Cancer
September 21, 2017 | Online

Overview

GOAL & PURPOSE

This program will provide an updated view of the optimal management of ALK Positive Lung Cancer.

  • Professor Tony Mok, MD, will discuss the detection of ALK as the first step to treatment.  The use of FISH and IHC is the current standard, and beyond, the role of NGS is under intensive investigation. The identification of different types of variants and the diverse mechanisms of resistance will be addressed in terms of implications for future management.
  • Prof. Solange Peters will cover the treatment landscape and management strategies for frontline therapy, after disease progression and beyond in advanced ALK-positive NSCLC.  ALK disease biology and resistance mechanisms to targeted therapies will be reviewed.  Based on the current state of knowledge, the best use of the various ALK inhibitors currently available and in development will be discussed.
  • Dr. Dan Tan will cover the clinical challenge the management of brain metastases in the unique molecular subset of lung cancer.  The differential profiles of currently available and emerging ALK inhibitors will be discussed as well as how they might be sequenced with other therapeutic modalities to achieve durable clinical activity.

What you should expect to learn

Course Objectives- After participating in this webinar learners will be able to:
  • Recognize the use of FISH and IHC to detect ALK; 
  • Demonstrate the different type of ALK  variants and mechanisms of resistance to ALK inhibitors;
  • Describe management strategies for front-line treatment and after disease progression;
  • Identify the differences in properties and CNS efficacy for ALK inhibitor;
  • Discuss the evolving paradigm for management of brain metastasis in ALK positive disease.

    Program Chair

    Professor Tony Mok, MD, FRCP(C), FRCP (Edin), FHKCP, FHKAM(Medicine), FASCO
    Chairman, Department of Clinical Oncology
    The Chinese University of Hong Kong 

    &

    Prof. Solange Peters MD, PhD

    M├ędecin Chef 
    Head Medical Oncology 
    Chair Thoracic Malignancies
    Oncology Department

    &

    Daniel SW Tan, MD, PhD, MBBS, MRCP, Bsc

    Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore
    Director, Experimental Cancer Therapeutics 
    Unit (Phase I Unit), NCCS
    Senior Clinician-Scientist, 
    Genome Institute of Singapore
    Associate Professor (Adj), 
    Duke-NUS Medical School

    Contact

    Program